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Introduction
Rare diseases, by definition, affect few people, but have 
a major impact on public health, being highlighted by the 
lack of relevant treatments or their cost-inefficiency, becom-
ing financially unviable for health domain [1, 2]. However, 
the health care of all patients is a value element of the right 
to health protection, being so a fundamental principle in a 
modern state. [3]. Thus, the problem of medical and phar-
maceutical assistance for people suffering from rare diseases 
has become one of the most difficult in the modern medi-
cine. In these circumstances, rare diseases are recognized as 
an important issue in the field of public health and in the 
budget allocation in healthcare. So, over time, the need to 
ensure an equitable access to patients’ treatment, regardless 
of the prevalence of the disease, has become a fundamental 
premise in creating policies and strategies supporting the 
multilateral development of the field [4-7].
Material and methods
The objective of the study was to identify the aspects 
related to the optimization of process of assurance with 
medicines the patients with rare diseases in the Republic 
of Moldova. For data collection, a retrospective study using 
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Abstract
Background: To ensure rare disease patients with medicines is a challenge for the health system. Treatments for rare diseases are very expensive, so 
the main financial burden for providing patients with medicines lies with the state. The objective of the study was to identify the aspects related to the 
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Treatment options and annual medicines requirements are set in accordance with national clinical protocols and international guidelines recommendations, 
the number of patients on the doctor’s records, as well as statistical data. 
Conclusions: Major problems in ensuring medicines to patients with rare diseases have been identified. The need of medicines is ensured by centralized 
public procurement, from the financial resources of the state budget, which were analyzed for the period of years 2018-2020.
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systemic analysis methods was performed. Data were col-
lected and processed with reference to health programs in 
the field of rare diseases and centralized public procure-
ment. The National Program  “Combating Rare Diseases” 
was identified and analyzed according to the following 
criteria: rare diseases included, medicines selected for the 
treatment of patients, the need of medicines for the years 
2018-2020 and procurement through tenders.
Results and discussion
Organizing medical and pharmaceutical assistance for 
patients with rare diseases in the Republic of Moldova re-
mains difficult because of the lack of a patient’s registry, 
standards for the diagnosis and treatment of patients and 
inaccessibility of medicines. Therefore, many patients suf-
fering from rare diseases cannot receive the necessary care. 
Also, it should be pointed out that medicines for the treat-
ment of rare diseases are very expensive and the main fi-
nancial burden for providing patients with the necessary 
medicines lies with the state.
The State guarantees the health protection of citizens, 
regardless of gender, age, presence of diseases, conditions, 
property and official status, the residence and other circum-
stances. Under the program of “State guarantees”, citizens 
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are provided with free healthcare, according to the list of 
diseases, whose treatment is reimbursed by the state.
The obligation to provide the rare disease patients with 
costless medicines is assigned to the component entities of 
the State, which are authorized to organize the medical care 
provided by the legislation of the Republic of Moldova for 
certain categories of citizens. They facilitate the accessibility 
of medicines to citizens and organize the supply of medi-
cines included in the lists and registers of people entitled to 
receive state assistance as provided by law.
National programs are an organized set of activities and 
services, established by law in order to prevent and treat 
diseases with serious consequences for the health of popu-
lation and, in some cases, with increased epidemiological 
risk. Prophylactic activities and the specific treatment of 
these diseases are financed from the state budget.
The national programs are designed, implemented and 
coordinated by the Ministry of Health, Labor and Social 
Protection. Their objectives are established by the same in-
stitution together with the National Health Insurance Com-
pany, representatives of professional scientific medical asso-
ciations, university clinics, research units and others.
The national program for rare diseases could solve 
many problems of the targeted patients. In this context, the 
Government of the Republic of Moldova adopted Decision 
no 636 of December 11, 2019, on the approval of the 
Government Action Plan for the years 2020-2023, in which 
to the part no VI “Social protection and health protection”, 
was included the point 6.13 “Intensification of measures to 
prevent communicable and non-communicable diseases”, 
listing the development and approval of a new National 
Program for Rare Diseases, to be completed by September 
2021 [8].
Likewise, in 2019, the Ministry of Health, Labor and 
Social Protection ordered the list of rare diseases, current 
for the Republic of Moldova.
At present, there are 12 health programs at the national 
level, including the National Program ”Combating Rare 
Diseases”, which aim to significantly improve the quality of 
care for “rare” patients and to solve the rare disease prob-
lems in the Republic of Moldova. In order to carry out the 
health programs, the Ministry of Health, Labor and Social 
Protection together with the Center for Centralized Health 
Procurement organize tenders for the procurement of spe-
cific medicines and sanitary materials for consumption in 
hospitals and outpatient, in compliance with legal provi-
sions on public procurement.
The National Program ”Combating Rare Diseases” has 
been running for several years. The treatment of rare dis-
eases began to be partially reimbursed from the budget of 
national programs in 2012. Then, 2 million 291 thousand 
lei were allocated for patients diagnosed with Wilson-
Konovalov, cystic fibrosis, phenylketonuria and pituitary in-
sufficiency diseases. In the subsequent years, the treatment 
for patients suffering from ß-thalassemia, early puberty, 
bullous epidermolysis and juvenile arthritis was also reim-
bursed. The volume of financial sources, allocated for the 
rehabilitation of the patients, also increased to over seven 
million lei in 2017 and 12 million lei in 2018. In 2020, for 
the diagnosis and treatment of rare diseases was planned 
over 39 million lei from the state budget, which is 15 million 
lei more compared to the amount provided for 2019 [9-10].
In 2020, the National Program “Combating Rare 
Diseases” includes 15 rare diseases, such as Wilson-
Konovalov, phenylketonuria, juvenile arthritis, ß-thalasse-
mia, hemophilia, pituitary insufficiency, early puberty, bul-
lous epidermolysis, epilepsy, diabetes insipidus, Addison’s 
disease, nonspecific ulcerative colitis / Crohn’s disease, pul-
monary hypertension, Duchenne muscular dystrophy and 
infectious diseases as cholera, malaria, toxoplasmosis.
Table 1
Medicines introduced in the national Program “Combating Rare Diseases”  
and selected according to the approved national clinical protocols
No National clinical protocol
Recommended medicines to be used in the 
treatment of the rare disease
The presence of medicine in the list of 
essential medicines
1. PCN-7
Idiopathic juvenile arthritis [11]
Tocilizumab, 80 mg/4 ml, vial Section 2.4. Antirheumatics
2. PCN-243
ß-thalassemia in children [12]
Deferoxamine, 500 mg, lyophilized powder Section 4.2. Non-specific medicines used in 
intoxications 
3. PCN-108
Hemophilia in children [13]
Coagulation factor VIII, 500 IU, lyophilized powder Section 11. Blood products and plasma 
substitutes
Coagulation factor IX, 500 IU, lyophilized powder
4. PCN-191
Hemophilia in adults [14]
Coagulation factor VIII, 1000 IU, lyophilized powder
Coagulation factor IX, 1000 IU, lyophilized powder
5. PCN-290
Epilepsy in adults [15]
Levetiracetam, 500 mg, tablets -
Levetiracetam, 250 mg, tablets -
6. PCN-258
Wilson’s disease in children [16]
D-Penicillamine, tablets -
Zinc Sulphate, tablets -
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Clear and detailed scales are needed to make clini-
cal decisions about diagnosing and treating such diseases. 
These are implemented by elaboration of clinical protocols 
that have a double beneficial effect: on the one hand it gives 
patients a quality and optimal standard, and on the other 
hand, it gives the doctor protection in the decision-making 
process. The national clinical protocols are developed on the 
basis of international guidelines based on evidence of clini-
cal and economic efficacy.
The list of rare diseases included in the National Program 
“Combating Rare Diseases” contains only six diseases for 
which national clinical protocols are developed, this rep-
resenting the clinical basis in the process of establishing 
the diagnosis and choosing the treatment. Approved clini-
cal protocols were consulted in the following rare diseases 
(tab. 1).
Also, in table 1 it is highlighted that the medicines 
selected for the listed diseases, except Levetiracetam, 
D-Penicillamine and Zinc Sulphate, are included in the 
list of essential medicines, approved by the Order of the 
Ministry of Health of the Republic of Moldova No 162 of 
April 23, 2007 and amended by the Order of the Ministry of 
Health of the Republic of Moldova No 144 of February 28, 
2011, which ensures the access to healthcare [17, 18].
In other cases, international guidelines and protocols 
were consulted to determine the medication. So, the list of 
medicines for the treatment of patients with rare diseases is 
elaborated according to the national clinical protocols and 
international guidelines and protocols, and the need for 
medicines to be purchased is calculated based on statistical 
data on the number of “rare” patients registered. Thus, in 
accordance with the provisions of the Order of the Ministry 
of Health, Labor and Social Protection No 948 of August 
10, 2018 on the organization of centralized procurement, 
the Ministry of Health, Labor and Social Protection submits 
to the Center for Centralized Health Procurement the need 
of medicines for the implementation of National Programs 
and treatment of rare diseases, according to the established 
diseases list.
According to the comparative analysis of the results of 
tenders organized for the procurement of medicines within 
the National Program “Combating rare diseases”, for the 
years 2018 - 2020 (the first 5 months of the year), the fol-
lowing data were obtained:
1. For 50 patients with Wilson’s disease, during the ana-
lyzed period, constant quantities of medicines according to 
the protocol were purchased;
2. 123 patients with phenylketonuria were provided with 
increasing amounts of nutrients free of phenylalanine and 
low in protein. Thus, in 2020, phenylalanine-free protein 
substitutes were purchased 3 times as much as in 2018, low 
protein pasta and flour 4 times and, respectively, 6 times as 
much as in 2018. In 2020, 4 new positions of nutrients were 
purchased (tab. 2).
3. Medicines for the treatment of juvenile arthritis, he-
mophilia in children, pituitary insufficiency, early puberty 
and diabetes insipidus were purchased annually in un-
changed quantities or slightly fluctuating quantities as in the 
case of bullous epidermolysis;
4. In the case of thalassemia, there is a considerable 
decrease of about 800% in the amount of Deferoxamine 
purchased and a decrease of about 600% in the amount of 
Levetiracetam purchased in the years 2019-2020, for the 
treatment of patients with epilepsy;
5. In adult hemophilia, coagulation factor VIII was 
achieved in 2019 1.5 times as much as in 2020, and the 
quantity of coagulation factor IX – decreased by 2 times;
6. Medicines for the treatment of Addison’s disease were 
purchased in quantities that differ from year to year, with a 
maximum in 2019 (fig. 1);
Fig. 1.  Medicines purchased for the treatment of patients with 
Addison’s disease, 2018-2020
7. Larger quantities of medicines were purchased for the 
treatment of pulmonary hypertension in 2020 compared to 
2019, which is explained by the increase in the number of 
patients;
8. The biologic medicine Golimumab (300 pre-filled sy-
ringes for 30 patients with nonspecific ulcerative colitis) was 
purchased for the first time in 2020, as well as medicines 
for patients with Duchenne muscular dystrophy and for the 
treatment of infectious diseases such as cholera, malaria and 
toxoplasmosis. 
The procurement of medicines within the program 
is done through tenders, announced by the order of the 
Ministry of Health, Labor and Social Protection. The Center 
for Centralized Health Procurement organizes public ten-
Table 2




1. Phenylalanine-free substitutes 
with different protein content
436.5 986.0 1344.0
2. Low protein flour 327.0 1890.0 2262.0
3. Low protein pasta 500.0 2160.0 2145.0
4. Low protein rice - - 900.0
5. Milk substitute, low protein drink - - 260.0
6. Low protein biscuits - - 1296.0
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ders in order to conclude a state contract for the supply of 
medicines as a part of the implementation of the decision. 
The evaluation of the offers and the award of the contract is 
done by each position of medicine at the lowest price with-
out VAT.
According to the results of the tenders published on the 
website of the Center for Centralized Health Procurement, 
for the concluded contracts, the following amounts were al-
located: for 2018 year – 5 million 895 thousand lei, for 2019 
– 5 million 194 thousand lei, and for 2020 – 28 million 678 
thousand lei (calculated for the first 5 months of the year).
In the treatment of rare diseases are used both medicines 
that have the status of orphans and authorized medicines, 
without orphan designations, but which have included in 
the indications a rare disease.
Following this aspect, it was performed a comparative 
analysis of the list of medicines for the treatment of rare 
diseases, authorized in the European Union and the list of 
medicines proposed for the treatment of “rare” patients in 
the Republic of Moldova. Therefore, the medicines included 
in the National Program “Combating rare diseases”, which 
are also found in the European list, such as tocilizumab, co-
agulation factor VIII and IX, somatropin, levetiracetam, go-
limumab, sildenafil, bosentan, iloprost and hydrocortisone 
were highlighted.
Conclusions
To facilitate the access to orphan medicinal products 
or medicines with rare disease indications and to build 
an infrastructure with all the necessary elements to sup-
port affected patients, it is necessary to develop, adopt and 
implement strategies and policies at national level, which, 
from the experience of other states, have positive results. 
In the Republic of Moldova, the State guarantees the pro-
tection of the health of patients with rare diseases through 
the National Program “Combating Rare Diseases”. Patients 
suffering from the rare diseases included in the list of dis-
eases of the Program and who are registered by a specialist, 
receive free medicines, reimbursed from the state budget, 
within the limit of purchased quantity.
However, during the study, major problems were stressed 
in the process of providing medicines to patients with rare 
diseases, such as:
– The lack of necessary medicines in the list of current 
rare diseases, as well as the absence of a common register of 
patients affected by rare diseases, making it impossible to 
analyze priorities in selecting diseases for inclusion in the 
National Program, which could so deprive other patients of 
free treatment;
– The absence of national clinical protocols for diseases 
included in the National Program, which aim to provide pa-
tients with qualitative and optimal treatment;
– The list of essential medicines that need regular upda-
ting and the assessment of the possibility of including several 
medicines for the treatment of rare diseases, thus ensuring 
safe access to care with effective and harmless medicines.
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